Novo Nordisk As Stock Current Asset
| NVO Stock | USD 106.80 0.67 0.63% |
Novo Nordisk AS fundamentals help investors to digest information that contributes to Novo Nordisk's financial success or failures. It also enables traders to predict the movement of Novo Stock. The fundamental analysis module provides a way to measure Novo Nordisk's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novo Nordisk stock.
At this time, Novo Nordisk's Non Current Assets Total are very stable compared to the past year. As of the 1st of December 2024, Total Current Assets is likely to grow to about 146.6 B, while Other Current Assets are likely to drop about 1.5 B. Novo | Current Asset |
Novo Nordisk AS Company Current Asset Analysis
Novo Nordisk's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Novo Nordisk Current Asset | 8.03 B |
Most of Novo Nordisk's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novo Nordisk AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Novo Current Asset Historical Pattern
Today, most investors in Novo Nordisk Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Novo Nordisk's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Novo Nordisk current asset as a starting point in their analysis.
Novo Nordisk Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Novo Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Novo Nordisk AS has a Current Asset of 8.03 B. This is 272.97% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current asset for all United States stocks is 14.05% higher than that of the company.
Novo Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novo Nordisk's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novo Nordisk could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics of similar companies.Novo Nordisk is currently under evaluation in current asset category among its peers.
Novo Nordisk ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novo Nordisk's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novo Nordisk's managers, analysts, and investors.Environmental | Governance | Social |
Novo Fundamentals
| Return On Equity | 0.89 | ||||
| Return On Asset | 0.21 | ||||
| Profit Margin | 0.35 % | ||||
| Operating Margin | 0.47 % | ||||
| Current Valuation | 473.9 B | ||||
| Shares Outstanding | 3.37 B | ||||
| Shares Owned By Institutions | 10.17 % | ||||
| Number Of Shares Shorted | 6.05 M | ||||
| Price To Earning | 37.42 X | ||||
| Price To Book | 27.80 X | ||||
| Price To Sales | 1.72 X | ||||
| Revenue | 232.26 B | ||||
| Gross Profit | 148.51 B | ||||
| EBITDA | 114.63 B | ||||
| Net Income | 83.68 B | ||||
| Cash And Equivalents | 37.47 B | ||||
| Cash Per Share | 16.57 X | ||||
| Total Debt | 27.01 B | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 0.92 X | ||||
| Book Value Per Share | 27.07 X | ||||
| Cash Flow From Operations | 108.91 B | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | 2.99 X | ||||
| Price To Earnings To Growth | 1.59 X | ||||
| Target Price | 941.31 | ||||
| Number Of Employees | 71.88 K | ||||
| Beta | 0.17 | ||||
| Market Capitalization | 472.8 B | ||||
| Total Asset | 314.49 B | ||||
| Retained Earnings | 104.84 B | ||||
| Working Capital | (30.01 B) | ||||
| Current Asset | 8.03 B | ||||
| Current Liabilities | 5.95 B | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 2.05 % | ||||
| Net Asset | 314.49 B | ||||
| Last Dividend Paid | 9.9 |
About Novo Nordisk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novo Nordisk AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novo Nordisk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novo Nordisk AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Novo Nordisk
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novo Nordisk position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will appreciate offsetting losses from the drop in the long position's value.Moving together with Novo Stock
| 0.78 | HLN | Haleon plc | PairCorr |
| 0.87 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.75 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.81 | ANRO | Alto Neuroscience, | PairCorr |
Moving against Novo Stock
| 0.84 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.75 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.72 | FNMFO | Federal National Mortgage | PairCorr |
| 0.61 | KB | KB Financial Group | PairCorr |
| 0.5 | ITCL | Banco Ita Chile | PairCorr |
The ability to find closely correlated positions to Novo Nordisk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novo Nordisk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novo Nordisk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novo Nordisk AS to buy it.
The correlation of Novo Nordisk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novo Nordisk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novo Nordisk AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novo Nordisk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Novo Nordisk Piotroski F Score and Novo Nordisk Altman Z Score analysis. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.224 | Dividend Share 9.9 | Earnings Share 2.99 | Revenue Per Share 60.698 | Quarterly Revenue Growth 0.214 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.